SL’s first and largest pharmaceutical facility begins commercial production   

Sri Lanka’s first and largest general oral solid and liquid dosage pharmaceutical manufacturing facility with state-of the-art WHO GMP and EU GMP compliance  has commenced its commercial production at Pitipana  in Homagama recently. ,

Morison Ltd., one of the pioneers of pharmaceutical manufacturing in Sri Lanka since 1959, announced the commencement of commercial production at its state-of the-art factory unveiled in late 2020.

The factory marked the launch of commercial production by manufacturing and releasing its 1^st commercial batches of Chlorphenamine Oral Solution and Paracetamol 500mg tablets to the market on the 26^th of May.

Marking a new era in the pharmaceutical manufacturing industry in Sri Lanka, with a commitment to increase access of high quality yet affordable medicines, Morison’s investment of Rs 4 billion in its new state-of-the-art pharmaceutical research and manufacturing facility, is  the highest  investment to date in the local pharma manufacturing industry, company officials said.  

The facility,  the first general oral solid and liquid dosage manufacturing plant in Sri Lanka, built as per European Union-Good Manufacturing Practice (EU-GMP) specifications and Quality Management Systems, has a capacity to manufacture over 5 Bn tablets and 2 Mn litres of liquid during two shifts,  which can cater up to 40% of the national demand.

Dinesh Athapaththu, Managing Director of Morison Limited said that . “With the launch of commercial production at the new facility, Morison continues its 60-year long mission to offer the highest quality products at affordable prices to Sri Lankans. 

 Living up to its purpose, Morison recently launched the 1^st locally manufactured SGLT-2, a new generation Diabetes molecule – Empagliflozin at a cost that is approximately 50% lesser than the prevailing market prices. According to the company, it is also working on a new product pipeline which will include some of the latest therapies predominantly in diabetic, cardiovascular and vitamin segments.

Further, leveraging the long-lasting relationships of the Hemas Group, Morison has signed up for contract manufacturing arrangements with a few leading regional pharmaceutical companies, which will be operationalized during the year.

Morison is hopeful that it can make a step change in the pharma manufacturing industry in Sri Lanka while helping to save much needed forex at this juncture and eventually build an export business.